Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy.

MLA

Nio, Kenta, et al. “Amrubicin Monotherapy for Patients with Extrapulmonary Neuroendocrine Carcinoma after Platinum-Based Chemotherapy.” Cancer Chemotherapy and Pharmacology, vol. 75, no. 4, Apr. 2015, pp. 829–35. EBSCOhost, https://doi.org/10.1007/s00280-015-2706-y.

APA

Nio, K., Arita, S., Isobe, T., Kusaba, H., Kohashi, K., Kajitani, T., Tamura, S., Hirano, G., Mitsugi, K., Makiyama, A., Esaki, T., Ariyama, H., Oda, Y., Akashi, K., & Baba, E. (2015). Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy. Cancer Chemotherapy and Pharmacology, 75(4), 829–835. https://doi.org/10.1007/s00280-015-2706-y

Chicago

Nio, Kenta, Shuji Arita, Taichi Isobe, Hitoshi Kusaba, Kenichi Kohashi, Tatsuhiro Kajitani, Shingo Tamura, et al. 2015. “Amrubicin Monotherapy for Patients with Extrapulmonary Neuroendocrine Carcinoma after Platinum-Based Chemotherapy.” Cancer Chemotherapy and Pharmacology 75 (4): 829–35. doi:10.1007/s00280-015-2706-y.